|
US6232071B1
(en)
*
|
1990-06-11 |
2001-05-15 |
Gilead Sciences, Inc. |
Tenascin-C nucleic acid ligands
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US6346611B1
(en)
*
|
1990-06-11 |
2002-02-12 |
Gilead Sciences, Inc. |
High affinity TGfβ nucleic acid ligands and inhibitors
|
|
US6762290B1
(en)
*
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
AU782620B2
(en)
*
|
1991-06-10 |
2005-08-11 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
HUP0202177A3
(en)
*
|
1999-07-14 |
2004-05-28 |
Alza Corp Mountain View |
Neutral lipopolymer and liposomal compositions containing same
|
|
EP2325337A1
(en)
*
|
2000-09-26 |
2011-05-25 |
Duke University |
RNA aptamers and methods for identifying the same
|
|
DK2431377T3
(en)
*
|
2001-10-26 |
2017-08-14 |
Noxxon Pharma Ag |
Modified L-nucleic acids
|
|
EA006746B1
(ru)
*
|
2001-11-09 |
2006-04-28 |
Айтек Фармасьютикалз |
Способы лечения глазных неоваскулярных заболеваний
|
|
US7094410B2
(en)
*
|
2002-03-02 |
2006-08-22 |
The Scripps Research Institute |
DNA vaccine against proliferating endothelial cells and methods of use thereof
|
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
JP4451308B2
(ja)
*
|
2002-07-24 |
2010-04-14 |
エフ．ホフマン−ラ ロシュ アーゲー |
ポリアルキレングリコール酸添加剤
|
|
CA2492463A1
(en)
|
2002-07-25 |
2004-02-05 |
Archemix Corporation |
Regulated aptamer therapeutics
|
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
WO2004050899A2
(en)
|
2002-12-03 |
2004-06-17 |
Archemix Corporation |
Method for in vitro selection of 2’-substituted nucleic acids
|
|
RU2234097C1
(ru)
*
|
2003-03-05 |
2004-08-10 |
Московский областной научно-исследовательский клинический институт |
Способ диагностики саркомы капоши
|
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
|
WO2004094614A2
(en)
|
2003-04-21 |
2004-11-04 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
CL2004001996A1
(es)
*
|
2003-08-08 |
2005-05-06 |
Eyetech Pharmaceuticals Inc |
Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
ES2674129T3
(es)
|
2004-02-12 |
2018-06-27 |
Archemix Llc |
Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
|
|
JP2007532662A
(ja)
*
|
2004-04-13 |
2007-11-15 |
（オーエスアイ）アイテツク・インコーポレーテツド |
高分子量の立体的な基へ抱合された核酸アプタマー
|
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
|
WO2006029258A2
(en)
|
2004-09-07 |
2006-03-16 |
Archemix Corp. |
Aptamer medicinal chemistry
|
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
|
EP1807107B1
(en)
|
2004-11-02 |
2011-09-07 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
MX2007016561A
(es)
|
2005-06-30 |
2008-03-10 |
Archemix Corp |
Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2.
|
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
|
EP1912676A2
(en)
*
|
2005-07-28 |
2008-04-23 |
(Osi) Eyetech, Inc. |
Cyclitol linker polymer conjugate
|
|
EP1931352B1
(en)
|
2005-08-22 |
2016-04-13 |
The Regents of The University of California |
Tlr agonists
|
|
KR100877824B1
(ko)
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
|
|
TW200804425A
(en)
*
|
2005-12-06 |
2008-01-16 |
Domantis Ltd |
Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
|
|
WO2007069068A2
(en)
*
|
2005-12-16 |
2007-06-21 |
Diatos |
Cell penetrating peptide conjugates for delivering nucleic acids into cells
|
|
JPWO2007080902A1
(ja)
*
|
2006-01-11 |
2009-06-11 |
協和発酵キリン株式会社 |
眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
|
|
AU2007223796B2
(en)
|
2006-03-08 |
2013-01-24 |
Astellas Us Llc |
Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
|
|
JP5425642B2
(ja)
|
2007-02-07 |
2014-02-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
合成ｔｌｒアゴニストの結合体およびそのための使用
|
|
US20110229498A1
(en)
|
2008-05-08 |
2011-09-22 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
|
ES2600781T3
(es)
*
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
KR101800833B1
(ko)
|
2009-03-20 |
2017-11-23 |
씨엘에스엔 래버러토리스, 인코퍼레이티드 |
폴리아민 유도체
|
|
WO2011061351A1
(en)
|
2009-11-23 |
2011-05-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
WO2012040524A1
(en)
*
|
2010-09-24 |
2012-03-29 |
Mallinckrodt Llc |
Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
|
|
US20150337308A1
(en)
|
2012-04-11 |
2015-11-26 |
Chu De Bordeaux |
Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
|
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
|
ES2912033T3
(es)
|
2012-10-23 |
2022-05-24 |
Caris Science Inc |
Aptámeros y usos de los mismos
|
|
EP2935628B1
(en)
|
2012-12-19 |
2018-03-21 |
Caris Life Sciences Switzerland Holdings GmbH |
Compositions and methods for aptamer screening
|
|
JP6249453B2
(ja)
|
2013-03-22 |
2017-12-20 |
国立大学法人 東京大学 |
Ｉｌ−１７に対するアプタマー及びその使用
|
|
EP3019243A4
(en)
|
2013-07-12 |
2017-03-15 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological conditions
|
|
CN105980615A
(zh)
|
2013-08-28 |
2016-09-28 |
卡里斯生命科学瑞士控股有限公司 |
寡核苷酸探针及其用途
|
|
PL3230316T3
(pl)
|
2014-12-11 |
2022-05-02 |
Bayer Healthcare Llc |
Leczenie zwyrodnienia plamki żółtej związanego z wiekiem z małą aktywną zmianą neowaskularyzacji naczyniówki
|
|
WO2016108264A1
(ja)
|
2014-12-29 |
2016-07-07 |
株式会社ボナック |
核酸分子を安定に含有する組成物
|
|
AU2016229076B2
(en)
|
2015-03-09 |
2022-01-20 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
IL256634B2
(en)
|
2015-06-29 |
2025-08-01 |
Caris Science Inc |
Therapeutic oligonucleotides
|
|
US10941176B2
(en)
|
2015-07-28 |
2021-03-09 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
EP4339288A3
(en)
|
2016-03-18 |
2024-06-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
US11697851B2
(en)
|
2016-05-24 |
2023-07-11 |
The Regents Of The University Of California |
Early ovarian cancer detection diagnostic test based on mRNA isoforms
|
|
US11293017B2
(en)
|
2016-05-25 |
2022-04-05 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
EP3332812A1
(en)
|
2016-12-07 |
2018-06-13 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Nucleic acid-based assembly and use of the assembly in cancer therapy
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
TW201906635A
(zh)
|
2017-07-04 |
2019-02-16 |
日商第一三共股份有限公司 |
伴隨視細胞變性的視網膜變性的疾病用藥
|
|
WO2019210097A1
(en)
*
|
2018-04-25 |
2019-10-31 |
Vitrisa Therapeutics, Inc. |
Aptamers with stability, potency or half-life for enhanced safety and efficacy
|
|
GB202405551D0
(en)
|
2024-04-19 |
2024-06-05 |
Vvb Bio Pte Ltd |
Combination treatment
|